MAXHEALTH Q4 FY26 Results Analysis: PAT Surges 34%, Margin Expands 151 bps

MAXHEALTH's Q4 FY26 numbers came in strong, with revenue of Rs. 2,143.00 Cr (+12.20% YoY) and PAT growth of +7.30% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

MAXHEALTH delivered strong FY26 results with revenue up 19.1% and PAT up 34.1%, driven by 151 bps margin expansion and tax benefits. Net Debt/EBITDA of 0.93x met management's target. Q4 recovery in occupancy (>75%) confirms resolution of insurance disruption. Kalinga acquisition (250 beds) and Lucknow expansion (712 beds) provide clear capacity growth path to 8,000 beds by FY28. CGHS pricing benefit of Rs.150-160 Cr expected in FY27 is a near-term catalyst. Key risks include rising finance costs (+42.5% YoY) and working capital pressure from receivables growth.

Key Investment Insights

Key Positives

• Revenue grew 19.1% YoY to Rs.8,373 Cr (full year FY26)
• PAT grew 34.1% YoY to Rs.1,442 Cr (full year FY26)
• EBITDA margin expanded 151 bps YoY to 28.3% in Q4
• Net Debt/EBITDA achieved at 0.93x, meeting management's target of below 1.0x
• Occupancy recovered to >75% in Q4 from 74% in Q3, confirming insurance disruption resolved
• Kalinga Hospital acquisition added 250 beds in Bhubaneswar for Rs.298 Cr
• Tax optimization reduced ETR from 23.5% to 13.9%, with Rs.14,148 Cr merger benefit
• Lucknow expansion of 712 beds approved, supporting 8,000 bed target by FY28

Risk Factors

• Finance costs rose 42.5% YoY to Rs.23,510 Cr, reflecting increased borrowings for expansion
• Trade receivables grew Rs.323 Cr YoY to Rs.970 Cr, indicating longer collection cycles
• Working capital stress visible - CFO/PAT declined to 1.13x from 1.34x
• Deferred tax charge of Rs.6,378 Cr in Q4 (52% of total tax) is unusually large
• Capex intensity high at 3.32x depreciation, aggressive expansion may pressure near-term FCF
• Employee costs grew 7.8% YoY but below revenue growth - productivity improvement but tight labor market